Boceprevir

Telaprevir & Boceprevir for Hepatitis C Sector Update: Health Care Insidermedicine In Depth – March 30, 2011 Merck takes its case for boceprevir to the FDA panel – FierceBiotech This is Merck’s big day at the FDA, as an expert panel takes a close look at the pros and cons regarding the hepatitis C drug boceprevir . Widely viewed as a likely winner at the agency, especially after an FDA team endorsed its efficacy … New Hepatitis C Drugs ( Boceprevir and Telaprevir) Receive Warm … Boceprevir’s cure rate reached 66 percent in Merck’s studies, an improvement over the current standard of care but less than the 79 percent reported for newly treated patients given the Vertex drug, called telaprevir. … Merck takes its case for boceprevir to the FDA panel … This is Merck’s big day at the FDA, as an expert panel takes a close look at the pros and cons regarding the hepatitis C drug boceprevir . Widely viewed as a likely winner at the agency, especially after an FDA team endorsed its efficacy … Earnings Preview: Merck report comes after drug OK (AP) | Stock … On Wednesday, a Food and Drug Administration advisory panel was to review Merck’s experimental drug for hepatitis C drug boceprevir , which has gotten expedited reviews from regulators in the U.S. and European Union. … HCV New Drug Research: Merck/ Boceprevir : FDA Hep C Panel “Live … In a preliminary review of boceprevir posted to its web site Monday, the FDA agreed with Merck’s clinical data demonstrating that the drug increases cure rates for hepatitis C over standard treatment. The FDA did raise some concerns … BiologyFool says: RT @adamfeuerstein : $MRK FDA panel — panelists split on question of using boceprevir in null responder patients. No formal vote.

Posted by on April 27, 2011. Filed under News. You can follow any responses to this entry through the RSS 2.0. You can skip to the end and leave a response. Pinging is currently not allowed.